Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Glandular Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Glandular Cell Neoplasm

Cancer Family

Glandular Cell Neoplasm

CI-CAN-00000188Explore in graph →

Non-malignant2,825 active trials43 approved drugs426 evidence items

NCIt: C7132

Overview
Statistics
Survival
Genomics166
Variants & evidence426
Drugs106
Trials10211
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (384)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 76–100 of 384 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.
· BMC Cancer · 2012 · PMID 22292935 · validated civic_curation pubmed
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.
· Clin Cancer Res · 2009 · PMID 19584151 · validated civic_curation pubmed
Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma.
· J Cell Mol Med · 2009 · PMID 19040416 · validated civic_curation pubmed
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
· Oncotarget · 2016 · PMID 26625204 · validated civic_curation pubmed
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
· J Clin Oncol · 2010 · PMID 20142587 · validated civic_curation pubmed
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
· J Clin Oncol · 2013 · PMID 23213094 · validated civic_curation pubmed
Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib.
· Onco Targets Ther · 2015 · PMID 26309414 · validated

Showing 76–100 of 384 publications

← Previous
1
2
3
4
5
…
16
Next →

civic_curation

Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis.

· PLoS One · 2014 · PMID 24740294 · validated civic_curation pubmed

Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.

· Anticancer Res · 2013 · PMID 23645741 · validated civic_curation pubmed

DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer.

· Eur J Cancer · 2011 · PMID 21458988 · validated civic_curation pubmed

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

· Breast Cancer Res Treat · 2012 · PMID 22418700 · validated civic_curation pubmed

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

· Lancet Oncol · 2015 · PMID 26596672 · validated civic_curation pubmed

Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.

· Clin Cancer Res · 2015 · PMID 25370464 · validated civic_curation pubmed

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

· J Clin Oncol · 2014 · PMID 24868024 · validated civic_curation pubmed

High expression of HEF1 predicts a poorer prognosis of hepatocellular carcinoma: A retrospective study.

· Mol Clin Oncol · 2016 · PMID 26893853 · validated civic_curation pubmed

CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.

· Oncotarget · 2016 · PMID 26894380 · validated civic_curation pubmed

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.

· Oncotarget · 2016 · PMID 26921265 · validated civic_curation pubmed

A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.

· J Thorac Oncol · 2011 · PMID 21847063 · validated civic_curation pubmed

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.

· Oncotarget · 2016 · PMID 27086918 · validated civic_curation pubmed

Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma.

· Oncotarget · 2016 · PMID 27092876 · validated civic_curation pubmed

The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma.

· Clin Cancer Res · 2001 · PMID 11751510 · validated civic_curation pubmed

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

· J Clin Oncol · 2009 · PMID 19667267 · validated civic_curation pubmed

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

· Am J Pathol · 2010 · PMID 20813970 · validated civic_curation pubmed

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

· Clin Cancer Res · 2013 · PMID 23470965 · validated civic_curation pubmed

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

· J Clin Oncol · 2013 · PMID 23382472 · validated civic_curation pubmed